Sulfasalazine Complete Guide To Uses, Dosage & Side Effects

Sulfasalazine is an anti-inflammatory medication consisting of a combination of 5-aminosalicylic acid (5-ASA, mesalamine) and the sulphonamide sulfapyridine. It is approved by the US Food and Drug Administration (FDA) for treating ulcerative colitis and rheumatoid arthritis, with additional off-label applications in dermatology for conditions such as psoriasis, alopecia areata, and lichen planus.

What is sulfasalazine?

Sulfasalazine, also known by brand names like Azulfidine, is a prodrug designed to deliver anti-inflammatory effects primarily in the colon. In the gut, bacterial azoreductases cleave the diazo bond, releasing 5-ASA (active locally in the intestine) and sulfapyridine (absorbed systemically). The sulfapyridine moiety acts as a carrier, enhancing colonic delivery of 5-ASA, which suppresses inflammation via inhibition of prostaglandin synthesis and other pathways.

Pharmacologically, sulfasalazine exhibits immunomodulatory, anti-inflammatory, and antiproliferative properties, making it versatile beyond gastroenterology and rheumatology into dermatological uses. Its oral bioavailability is low (10-15% for intact drug), with peak plasma levels of metabolites occurring 3-24 hours post-dose. Metabolism varies by acetylator status: slow acetylators have higher sulfapyridine levels, increasing side effect risk.

What is sulfasalazine used for?

Sulfasalazine is FDA-approved for:

• Mild to moderate ulcerative colitis and as adjunctive therapy in severe cases
• Prolonging remission in ulcerative colitis
• Rheumatoid arthritis in adults and polyarticular juvenile idiopathic arthritis unresponsive to other NSAIDs

In dermatology, uses are off-label and supported variably by evidence:

• Psoriasis and psoriatic arthritis: Effective in some cases due to anti-inflammatory effects
• Alopecia areata: Reported efficacy in patchy and extensive forms
• Lichen planus: Including oral variants

Other non-approved dermatological indications, based on case reports or small series, include:

• Pemphigus vulgaris and foliaceus
• Hidradenitis suppurativa
• Pyoderma gangrenosum
• Behçet disease
• Sweet syndrome
• Neutrophilic dermatoses
• Subcorneal pustular dermatosis
• Pityriasis lichenoides et varioliformis acuta (PLEVA)
• Erythema nodosum
• Haemorrhagic dermatoses

Except for psoriasis, alopecia areata, and lichen planus, evidence is limited to isolated reports. Its role in dermatology stems from disease-modifying antirheumatic drug (DMARD) properties, akin to its rheumatoid arthritis use.

Mechanism of action

The precise mechanism remains incompletely understood but multifactorial:

• Inhibition of follicular 5-lipoxygenase in keratinocytes, reducing leukotriene B4
• Blocks voltage-dependent potassium channels in T lymphocytes
• Inhibits nuclear factor kappa B (NF-κB)
• Reduces epidermal proliferation and differentiation
• Decreases adhesion molecule expression
• Suppresses inducible nitric oxide synthase

These actions contribute to its efficacy in inflammatory dermatoses.

Side effects of sulfasalazine

Side effects are more common in slow acetylators due to elevated sulfapyridine levels.

Common, harmless, transient effects:

• Orange-yellow discoloration of urine, skin, soft contact lenses
• Reversible oligospermia and infertility (affects sperm motility)
• Headache, nausea, anorexia, gastric distress

Rare but serious effects:

• Blood dyscrasias: agranulocytosis, aplastic anaemia, haemolytic anaemia, leukopenia, megaloblastic anaemia, thrombocytopenia
• Hepatitis
• Interstitial nephritis, reversible renal failure
• Sulphonamide hypersensitivity: serum sickness, erythema multiforme, exfoliative dermatitis, Stevens–Johnson syndrome, toxic epidermal necrolysis
• Pulmonary eosinophilia, alveolitis, fibrosis
• Pancreatitis
• Worsening colitis
• Reversible oligospermia (noted above)

Potential cutaneous adverse events:

• Urticaria
• Maculopapular rash
• Exfoliative dermatitis
• Photosensitivity
• Blue-grey skin pigmentation
• Erythema nodosum
• Toxic epidermal necrolysis
• Drug reaction with eosinophilia and systemic symptoms (DRESS)
• Acute generalized exanthematous pustulosis (AGEP)

Serious skin reactions like Stevens-Johnson syndrome, TEN, DRESS, and AGEP require immediate discontinuation. Common early effects include headache, nausea, abdominal pain; photosensitivity necessitates sunscreen use. Dose-dependent blood count reductions and liver enzyme elevations occur; reversible infertility affects males. Skin may become sun-sensitive, with orange urine/skin discoloration being harmless.

Monitoring sulfasalazine

As dermatological uses are off-label, obtain informed consent before starting.

Pretreatment workup:

• Full blood count
• Liver function tests
• Renal function
• Urinalysis

Ongoing monitoring:

• Full blood count, liver, and renal function every 2-4 weeks for first 3 months, then every 8-12 weeks for next 3 months, then 12-weekly

Discontinue if persistent blood abnormalities, severe GI symptoms, or rash develop. Repeat tests after dose increases.

Dosing of sulfasalazine

Start low to minimize side effects:

• Initial: 500 mg daily, increase by 500 mg weekly
• Maintenance: 2–3 g daily (max 4 g/day)

Divide doses 4-6 times daily; consider enteric-coated for GI tolerance.

Drug interactions

• Folate antagonists (e.g., methotrexate): Sulfasalazine impairs folate absorption; supplement folic acid
• Antibiotics: Reduce cleavage, lowering 5-ASA delivery
• Phenytoin, warfarin: Sulfapyridine displaces from protein binding
• Digoxin: Reduced absorption
• Oestrogenic drugs: Ethinyloestradiol levels increase

Contraindications and cautions

Contraindications:

• Hypersensitivity to salicylates, sulphonamides, or components
• Porphyria
• Sulphonamide allergy

Cautions: Impaired renal/hepatic function, G6PD deficiency, slow acetylator status.

Sulfasalazine and pregnancy

US FDA: Pregnancy Category B (no evidence of risk in humans; animal studies show no fetal harm).

Australian TGA: Category A (widely used in pregnancy without proven malformations).

However, caution advised due to limited data; benefits must outweigh risks. Sulfapyridine crosses placenta; monitor neonate for jaundice, haemolysis (especially G6PD deficiency). Compatible with breastfeeding; infant <2 months at higher kernicterus risk.

Frequently Asked Questions

What conditions does sulfasalazine treat in dermatology?

Sulfasalazine treats off-label psoriasis, psoriatic arthritis, alopecia areata, lichen planus, pemphigus, hidradenitis suppurativa, and others based on case reports.

Does sulfasalazine cause skin side effects?

Yes, including rash, photosensitivity, urticaria, and severe reactions like Stevens-Johnson syndrome or TEN. Use sunscreen and monitor closely.

Is orange urine from sulfasalazine normal?

Yes, harmless discoloration of urine/skin occurs due to metabolites; reversible on discontinuation.

How is sulfasalazine monitored?

Blood counts, liver/kidney function every 2-4 weeks initially, then less frequently.

Can sulfasalazine be used in pregnancy?

Generally safe (FDA Category B, TGA A), but consult physician for risk-benefit assessment.

Similar Articles

Alarming Rise in Self-Harm in Young People

Alarming Rise in Self-Harm in Young People

Skin Signs Of Non-Accidental Injury: Expert Guide For Clinicians

Lichen Simplex Of The Scrotum: Diagnosis And Treatment

Labial Adhesion In Prepubertal Girls: What Parents Need To Know

Thrush In Men: 5 Signs, Causes, And Treatment Options

Author

medha deb

 

Medha Deb is an editor with a master's degree in Applied Linguistics from the University of Hyderabad. She believes that her qualification has helped her develop a deep understanding of language and its application in various contexts.

Read full bio of medha deb